Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate safety, immunogenicity, and preliminary anti-tumor activity
of a multi-peptide immunotherapy (BB-MPI-03) at three peptide+adjuvant dose levels. The
peptides stimulate cytotoxic T-cells targeting oncofetal antigen (OFA). Subjects with AML,
MM, sMM, or MDS who are off treatment and with stable disease or better, or who are not
eligible for or refuse allogeneic HSCT are to be enrolled. The study will be conducted at 2
to 4 study centers in the US.